---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-025506"
form_type: "8-K"
ticker: "EMMA"
cik: "0000822370"
company_name: "Emmaus Life Sciences, Inc."
filed_at: "2023-03-31T23:59:59+00:00"
generated_at: "2026-06-17T08:44:30.518887+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Emmaus Life Sciences reports FY2022 net loss of $10.6M; going concern doubt raised

## Summary
- Net revenues $18.4M, down 10.7% from $20.6M in 2021; operating loss widened to $6.6M from $6.1M.
- Net loss attributable to common stockholders $10.6M ($0.21 per share) vs $15.9M ($0.32) in 2021.
- Cash and cash equivalents $2.0M at Dec 31, 2022, down from $2.3M; substantial doubt about going concern.
- Audit report includes going-concern qualification; company cites Covid disruptions and higher distributor discounts.
- Marketing authorizations for Endari obtained in Qatar, Kuwait, and UAE in 2022; management cites strong sales momentum.

## SEC filing metadata
- accession: 0001213900-23-025506
- form_type: 8-K
- ticker: EMMA
- cik: 0000822370
- company_name: Emmaus Life Sciences, Inc.
- filed_at: 2023-03-31T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/822370/000121390023025506/0001213900-23-025506-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/822370/000121390023025506/ea176042-8k_emmauslife.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-025506
- JSON: https://secwatch.observer/filing/0001213900-23-025506.json
- Plain text: https://secwatch.observer/filing/0001213900-23-025506.txt

## Key facts
- Earnings Releases
  Emmaus Life Sciences, Inc. reported the year ended December 31, 2022 results: revenue $18.4 million, net income ($10.6 million, or $0.21 per share), EPS $(0.21) per share.
  - Period: the year ended December 31, 2022
  - Revenue: $18.4 million
  - Net income: ($10.6 million, or $0.21 per share)
  - EPS: $(0.21) per share
  - Result: reported results
  source text: earlier in 2022, so the sales momentum is strong for the upcoming year.” Financial and Operating Results Net Revenues. Net revenues for the year ended December 31, 2022 were $18.4 million, compared to $20.6 million for 2021. Although sales volume as measured by number of boxes of Endari sold increased compared to 2021, net revenues were adversely affected by
  evidence_url: https://www.sec.gov/Archives/edgar/data/822370/000121390023025506/0001213900-23-025506-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.